IL102079A - Use of PNAC inhibitors in pharmaceuticals - Google Patents

Use of PNAC inhibitors in pharmaceuticals

Info

Publication number
IL102079A
IL102079A IL10207992A IL10207992A IL102079A IL 102079 A IL102079 A IL 102079A IL 10207992 A IL10207992 A IL 10207992A IL 10207992 A IL10207992 A IL 10207992A IL 102079 A IL102079 A IL 102079A
Authority
IL
Israel
Prior art keywords
inhibitor
cells
inhibitors
canps
cell
Prior art date
Application number
IL10207992A
Other languages
English (en)
Hebrew (he)
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of IL102079A publication Critical patent/IL102079A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL10207992A 1991-06-03 1992-06-02 Use of PNAC inhibitors in pharmaceuticals IL102079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR91100238 1991-06-03

Publications (1)

Publication Number Publication Date
IL102079A true IL102079A (en) 1996-10-16

Family

ID=10940713

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10207992A IL102079A (en) 1991-06-03 1992-06-02 Use of PNAC inhibitors in pharmaceuticals

Country Status (14)

Country Link
EP (1) EP0549742B1 (fr)
JP (1) JP3703828B2 (fr)
AT (1) ATE263574T1 (fr)
AU (1) AU646961B2 (fr)
CA (1) CA2088671C (fr)
DE (1) DE69233337T2 (fr)
DK (1) DK0549742T3 (fr)
ES (1) ES2215162T3 (fr)
GR (1) GR1001044B (fr)
IL (1) IL102079A (fr)
NO (1) NO930305L (fr)
NZ (1) NZ243003A (fr)
PT (1) PT100560A (fr)
WO (1) WO1992021373A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT666755E (pt) * 1992-09-09 2003-09-30 Us Gov Health & Human Serv Inibicao da infeccao pelo vih
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
EP0626178A1 (fr) * 1993-05-17 1994-11-30 Ciba-Geigy Ag Utilisation d'inhibiteurs de la protease du VIH dans le traitement des maladies tumorales
US20030060435A1 (en) 1994-05-31 2003-03-27 Serge Carillo Method of cancer treatment by p53 protein control

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815962D0 (en) * 1988-07-05 1988-08-10 Univ London Pharmaceutical preparation & method for promoting reinnervation of muscle fibers

Also Published As

Publication number Publication date
EP0549742A1 (fr) 1993-07-07
NO930305L (no) 1993-02-26
CA2088671A1 (fr) 1992-12-04
DE69233337D1 (de) 2004-05-13
NO930305D0 (no) 1993-01-29
PT100560A (pt) 1993-07-30
NZ243003A (en) 1997-07-27
AU646961B2 (en) 1994-03-10
EP0549742B1 (fr) 2004-04-07
DE69233337T2 (de) 2005-05-04
ES2215162T3 (es) 2004-10-01
DK0549742T3 (da) 2004-07-26
JPH06502188A (ja) 1994-03-10
CA2088671C (fr) 1997-01-14
JP3703828B2 (ja) 2005-10-05
ATE263574T1 (de) 2004-04-15
GR1001044B (el) 1993-04-28
WO1992021373A1 (fr) 1992-12-10
AU1907392A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
JP2806634B2 (ja) 前立腺癌，胃癌および乳癌に関連する腫瘍を抑制するための医薬製剤
EP3638231B1 (fr) Tinostamustine destinée à être utilisée dans le traitement de la leucémie prolymphocytaire à lymphocytes t
US10907161B2 (en) Synthetic RIG-I-like receptor agonists
Mori et al. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice
WO2021012886A1 (fr) Composition pharmaceutique combinée antinéoplasique et son application
EP3789396B1 (fr) Peptide synthétique sp2 et son utilisation
US20180236034A1 (en) Compositions and Methods of Using Anti-Mullerian Hormone for Treatment of Infertility
CA2088671C (fr) Utilisation d'inhibiteurs de proteinases dependant de l'ion ca2+ dans les preparations pharmaceutiues
Crowther et al. Biology of cell killing by 1-β-D-arabinofuranosylcytosine and its relevance to molecular mechanisms of cytotoxicity
CN105963699A (zh) Fats作为黑色素瘤免疫治疗的靶点及应用
KR930004596B1 (ko) 신규 림포킨(lymphokine) 및 이에 대해 특이성을 갖는 모노클로날(monoclonal) 항체의 제조 방법
US6511959B1 (en) Use of calcium-activated neutral protease (CANP) inhibitors in pharmaceutical preparations
AU746637B2 (en) Fertility improving composition and application thereof
US6482833B2 (en) Immunotherapeutic anti-cancer pharmaceutical compositions
US7163919B2 (en) Anticancer composition
CN114306306B (zh) 2-溴棕榈酸在制备治疗生精功能障碍相关疾病的药物中的应用
CN112569338B (zh) Tdfa在制备预防和/或治疗眼表炎症疾病的药物中的应用
KR102608364B1 (ko) Sirt7 억제제를 포함하는 알레르기 질환 예방 또는 치료용 약학적 조성물
EP0168217A2 (fr) Procédé d'extraction d'une substance semblable au facteur de nécrose des tumeurs
El Sahwi et al. In vivo study of the embryotoxic activity of leukocytes
KR20030028855A (ko) 렉틴으로 강화된 겨우살이 추출물을 유효성분으로 하는항암제용 조성물
El Sahwi et al. Embryotoxic effect of homogenized polymorphs, macrophages, endometrial and liver cells in vitro
KR20220149245A (ko) 조골세포 미토콘드리아에 작용하여 골형성 촉진 유도용 또는 골질환 치료용 조성물
WO2000006546A1 (fr) Compositions pharmaceutiques immunotherapeutiques anticancereuses
KIRBY suggests that the unimplanted egg derives little specific advantage

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees